Posts Tagged ‘researchers

January 10, 2022
Our Take: Flurry of M&A activity marks end of 2021, spills over into 2022
Read More
December 19, 2021
Our Take: 2021 in the rearview
Read More
December 13, 2021
Our Take: Update on the omicron variant, vaccines, and other COVID-19 treatments
Read More
December 06, 2021
Our Take: FDA panel votes to authorize Merck, Ridgeback’s molnupiravir, despite lower efficacy in final trial results
Read More
November 22, 2021
Our Take: HHS will require health insurers to report data on prescription drug costs and coverage
Read More
November 15, 2021
Our Take: Public health officials face steep challenge in fight against COVID-19 misinformation, KFF survey indicates
Read More
November 08, 2021
Our Take: New COVID-19 mandates could require millions more to be vaccinated by Jan. 4 unless lawsuits prevail
Read More
November 01, 2021
Our Take: Two new PBMs target high drug prices, lack of transparency
Read More
October 25, 2021
Our Take: Value-based payment for prescription drugs: Will industry or the feds lead the way?
Read More
October 18, 2021
Our Take: Boehringer Ingelheim joins list of drugmakers facing possible penalties for violating 340B statute
Read More
October 11, 2021
Our Take: Intermountain, Presbyterian, SSM Health launch member-led company to ‘transform’ digital health care
Read More
October 04, 2021
Our Take: Merck, Ridgeback could be first to receive EUA for COVID-19 pill
Read More
September 27, 2021
Our Take: Walgreens to invest nearly $1 billion in Shields Health Solutions
Read More
September 20, 2021
Our Take: Northwell Health, Walgreens form new affiliation to improve care for tre-state area
Read More

Sign up for Our Take
the weekly strategic brief for Health Care Executives

Reach out to us

Gainey Corporate Center
8777 N Gainey Center Dr, Ste 205
Scottsdale, AZ 85258
(480) 923-0802

Sign up for Our Take
the weekly strategic brief for Health Care Executives

[contact-form-7 id="321" title="Footer Newsletter"]

Posts Tagged ‘researchers

Our Take: Flurry of M&A activity marks end of 2021, spills over into 2022

Our Take: 2021 in the rearview

Our Take: Update on the omicron variant, vaccines, and other COVID-19 treatments

Our Take: FDA panel votes to authorize Merck, Ridgeback’s molnupiravir, despite lower efficacy in final trial results

Our Take: HHS will require health insurers to report data on prescription drug costs and coverage

Our Take: Public health officials face steep challenge in fight against COVID-19 misinformation, KFF survey indicates

Our Take: New COVID-19 mandates could require millions more to be vaccinated by Jan. 4 unless lawsuits prevail

Our Take: Two new PBMs target high drug prices, lack of transparency

Our Take: Value-based payment for prescription drugs: Will industry or the feds lead the way?

Our Take: Boehringer Ingelheim joins list of drugmakers facing possible penalties for violating 340B statute

Our Take: Intermountain, Presbyterian, SSM Health launch member-led company to ‘transform’ digital health care

Our Take: Merck, Ridgeback could be first to receive EUA for COVID-19 pill

Our Take: Walgreens to invest nearly $1 billion in Shields Health Solutions

Our Take: Northwell Health, Walgreens form new affiliation to improve care for tre-state area

Sign up for Our Take
the weekly strategic brief for Health Care Executives

share

Reach out to us

Sign up for Our Take
the weekly strategic brief for Health Care Executives

Stay Connected

Posts Tagged ‘researchers

Sign up for Our Takethe weekly strategic brief for Health Care Executives

share

Reach out to us

Sign up for Our Takethe weekly strategic brief for Health Care Executives

Stay Connected

Sign up for Our Take
the weekly strategic brief for Health Care Executives

Sign up for Our Take
the weekly strategic brief for Health Care Executives